Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jon B. Bruss"'
Publikováno v:
Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Acinetobacter baumannii and Enterobacterales are identified as urgent threats, and multidrug-resistant (MDR) Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing pathogens are identified as serious threats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8da3261238174ae7299d71e61ef738
http://europepmc.org/articles/PMC8448162
http://europepmc.org/articles/PMC8448162
Autor:
John N. van den Anker, Gail L. Jungbluth, Nancy K. Hopkins, Jon B. Bruss, Rosie P. Grzebyk, Susan M. Abdel-Rahman, Ian R Welshman, Gregory L. Kearns
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:413-422
The impact of age on linezolid disposition during the first few months of life has not been previously investigated. We characterized linezolid pharmacokinetics after a single, 10.0-mg/kg intravenous dose in 42 infants stratified as follows: group 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c51cc77cf29da828e0b9b1f506d519c
https://doi.org/10.1016/s0009-9236(03)00226-1
https://doi.org/10.1016/s0009-9236(03)00226-1
Autor:
Barbara Edge-Padbury, Stuart P. Adler, Sharon Naberhuis-Stehouwer, Jon B. Bruss, Barbara Jantausch, Pio Lopez, María Morfin, Jaime G. Deville
Publikováno v:
Pediatric Infectious Disease Journal. 22:S164-S171
Background Nosocomial infections, particularly hospital-acquired pneumonia (HAP) and bacteremia, are an increasing concern in pediatric hospitals and pediatric intensive care units. Gram-positive pathogens are a leading cause of these infections in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6df7fddc2a77e0d362e85d2a3b89153
https://doi.org/10.1097/01.inf.0000086956.45566.55
https://doi.org/10.1097/01.inf.0000086956.45566.55
Autor:
Lori E. R. Patterson, Sheldon L. Kaplan, Barbara Edge-Padbury, Amando Martin, Ram Yogev, María Morfin, Jon B. Bruss, Stuart P. Adler, Sharon Naberhuis-Stehouwer
Publikováno v:
Pediatric Infectious Disease Journal. 22:S172-S177
Gram-positive pathogens are a major cause of complicated skin and skin structure infections (CSSSIs) in children. Many pathogens are developing decreased susceptibility to currently used antibiotics, increasing the need for new therapies. Linezolid i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f36b3a422f0a0b7c68c98b730b7df80
https://doi.org/10.1097/01.inf.0000088671.35064.7c
https://doi.org/10.1097/01.inf.0000088671.35064.7c
Autor:
Kenneth Wible, Lisa Saiman, Sharon Naberhuis-Stehouwer, Jon B. Bruss, Johhanna Goldfarb, Sheldon A Kaplan, Barbara Edge-Padbury
Publikováno v:
Pediatric Infectious Disease Journal. 22:S193-S200
BACKGROUND Linezolid, an oxazolidinone, is effective in the treatment of adults and children with community-acquired and nosocomial pneumonia and uncomplicated and complicated skin and skin structure infections (SSSIs), including infections caused by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0a67512225e4c4f44be3f0fffbb798
https://doi.org/10.1097/01.inf.0000087022.58089.d8
https://doi.org/10.1097/01.inf.0000087022.58089.d8
Autor:
María Morfin, Barbara Edge-Padbury, Sheldon L. Kaplan, H. Cody Meissner, Wanda Wenman, Timothy R. Townsend, Jon B. Bruss, Sharon Naberhuis-Stehouwer
Publikováno v:
Pediatric Infectious Disease Journal. 22:S186-S192
Background Linezolid is an effective and well-tolerated antibiotic for the treatment of Gram-positive infections, including hospital and community-acquired pneumonia and complicated and uncomplicated skin and skin structure infections. In adults line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c58575ecc0961308fd9a6770f27bcfc
https://doi.org/10.1097/01.inf.0000087021.20838.d9
https://doi.org/10.1097/01.inf.0000087021.20838.d9
Autor:
Jon B. Bruss, George R. Siber
Publikováno v:
Clinical Diagnostic Laboratory Immunology. 6:464-470
Pertussis in infants is often severe, resulting in prolonged hospitalization. Treatment is limited to supportive care. Antibiotics do not significantly alter the course of the disease unless administered during the catarrhal phase. Therapies directed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5783ef182721c092f49c4f09f070abfa
https://doi.org/10.1128/cdli.6.4.464-470.1999
https://doi.org/10.1128/cdli.6.4.464-470.1999
Autor:
Simon Dobson, Mohsin Dhalla, George R. Siber, Scott A. Halperin, Richard Malley, Jon B. Bruss, James McIver
Publikováno v:
The Pediatric Infectious Disease Journal. 18:505-511
Pertussis in infants is often severe, resulting in complications and prolonged hospitalization. Treatment is limited to supportive care. Antibiotics do not significantly alter the course of the disease. Therapies directed at pertussis toxin, a major
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f971e29aebdf50db6cb6d46d550b3dc
https://doi.org/10.1097/00006454-199906000-00006
https://doi.org/10.1097/00006454-199906000-00006
Autor:
Ori D. Rotstein, Anita Das, Kimberley S. Severin, Jon B. Bruss, John B. Cone, Samuel E. Wilson, Ross Ristagno, Joseph S. Solomkin, Brian S. Murphy
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 56(12)
In clinical trials of complicated intra-abdominal infections, assessment of adequacy of the initial surgical approach to the management of the infection is of considerable importance in determining outcome. Antibiotic therapy would not be expected to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee8dda65eb9ff486f2df8abaa550c1f6
https://pubmed.ncbi.nlm.nih.gov/23463643
https://pubmed.ncbi.nlm.nih.gov/23463643
Autor:
Kenneth J. Tack, Carter D. Brooks, Don Young, Marie T. Borin, Robert T. Cass, Jon B. Bruss, Nancy A. Havrilla
ACHN-490 is an aminoglycoside with activity against multidrug-resistant pathogens, including those resistant to currently used aminoglycosides. Two randomized, double-blind, placebo-controlled clinical studies investigated the pharmacokinetics (PK),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2abf7c3f7bf9dfcf2a4ce280367cac9
https://europepmc.org/articles/PMC3232771/
https://europepmc.org/articles/PMC3232771/
